NGeneBio - 2025 Company Profile, Funding & Competitors

Q: Where is NGeneBio located?

NGeneBio is located in Seoul, South Korea .

Company Details

NGeneBio is offering products for in vitro diagnostic of oncology. It offers breast cancer detection kit, NSC for solid tumor detection, hematological malignancy panel, along with bioinformatics analysis software, and a genetic test for the short tandem repeat. The product portfolio of the company includes next-generation sequencing (NGS)-based in vitro diagnostics (IVD) panel and clinical analysis software (SW) for applications in molecular diagnostics (MDx) and companion diagnostics (CDx). It can detect the mutation in BRCA genes.

Website
Social
Email ID: @ngenebio.com
Phone Number: +82

Key Metrics

Founded Year

2015

Location

Seoul, South Korea

Stage

Public

Total Funding

in 2 rounds

Latest Funding Round

Investors

Korea Investment Holdings & 4 more

Ranked

13^th among 164 active competitors

Similar Companies

Foundation Medicine &

Exit Details

Public

NGeneBio has raised a total funding of $12.9M over 2 rounds. Its first funding round was on 2017. Its latest funding round was a Series B round on Dec 03, 2018 for $11M. 4 investors participated in its latest round, which includes UTC Investment, DSC Investment, Korea Investment Holdings and KT Investment.

NGeneBio has 5 institutional investors including Korea Investment Holdings, UTC Investment and DSC Investment.

Here is the list of recent funding rounds of NGeneBio:

Date of funding	Funding Amount	Round Name	Post money valuation	Revenue multiple	Investors
Dec 03, 2018	$11M	Series B	5083146	8845972	DSC Investment, IMM Investment, and
2017	$1.9M	Seed	7366	4878	-

Access funding benchmarks and valuations. Sign up today!

View details of NGeneBio's funding rounds and investors

Top competitors of NGeneBio include Foundation Medicine, Personalis and MedGenome. Here is the list of Top 10 competitors of NGeneBio, ranked by 秘密研究所 score :

Overall Rank	Company Details	Short Description	Total Funding	Investors	秘密研究所 Score
1st	Foundation Medicine 2010, Cambridge (United States), Acquired	Provider of genomics-based diagnostics test for cancer	$96.5M	Redmile Group, Roche听&补尘辫;听	70/100
2nd	Personalis 2011, Menlo Park (United States), Public	Provider of genomic sequencing and diagnosis software for the healthcare industry	$87.3M	Wellington Shields, Lightspeed Venture Partners听&补尘辫;听	64/100
3rd	MedGenome 2013, Bengaluru (India), Series D	Provider of DNA sequencing, bioinformatics, and multiomics services	$217M	Sofina, Papillon Capital听&补尘辫;听	61/100
4th	Lantern Pharma 2013, Dallas (United States), Public	Developing drug and companion diagnostics for multi-drug resistant cancers	$7.12M	Bios Partners, Health Wildcatters听&补尘辫;听	59/100
5th	Mirvie 2019, San Francisco (United States), Series B	Provider of non-invasive diagnostic tests for pregnant women	$90M	Foresite Capital, Correlation Ventures听&补尘辫;听	58/100
6th	Burning Rock 2014, Guangzhou (China), Public	Developer of personalised diagnostic and treatment services based on genomic big data analysis	$203M	Northern Light Venture Capital, GIC听&补尘辫;听	58/100
7th	Zhejiang Nuhui Health Technology 2013, Beijing (China), Public	Provider of early cancer screening and testing services	$152M	Sherpa Venture Capital, Zhejiang Haibang Investment Management听&补尘辫;听	57/100
8th	Veritas Genetics 2014, Danvers (United States), Acquired	Provider of genetic testing products	$53.4M	Trustbridge Partners, Alpha Square Group听&补尘辫;听	56/100
9th	Novogene Corporation 2011, Beijing (China), Series B	Provider of genomic services and solutions	$75M	China Merchants Capital, SDIC Innovation听&补尘辫;听	54/100
10th	3billion 2016, Seoul (South Korea), Public	Provider of AI-driven clinical diagnostic testing platform for rare genetics disease	$25.7M	JW Asset Management, Korea Development Bank Europe听&补尘辫;听	51/100
13th	2015, Seoul (South Korea), Public	In vitro cancer diagnostic products	$12.9M	UTC Investment, DSC Investment听&补尘辫;听	50/100